Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug tests will prevent repeat of Northwick Park trial

16.12.2008
Scientists investigating the 2006 Northwick Park drug-trial disaster that left six healthy volunteers hospitalised say they have developed new pre-clinical tests that could have stopped the trial from ever going ahead.

But Dr Stephen Poole, speaking at the British Pharmacological Society’s Winter Meeting in Brighton today (Tuesday), said that research is still “ongoing” to understand why the drug had such an adverse effect in the clinic but not in pre-clinical testing.

Describing the incident as “the most obvious setback for medicines testing since thalidomide”, Dr Poole and his colleagues, from the National Institute for Biological Standards and Control (NIBSC) have, with new tests, successfully reproduced the devastating reaction suffered by the volunteers using human cells in the test tube (in vitro).

Standard preclinical in vitro tests on TGN1412 – the immunotherapy drug responsible for the Northwick Park disaster – failed to predict the catastrophic reaction that would occur when TGN1412 was administered to human subjects.

TGN1412 is from a class of drugs developed to re-balance the immune system for the treatment of autoimmune diseases, where the immune system has started to attack the body, such as rheumatoid arthritis and multiple sclerosis.

The Northwick Park disaster resulted in the UK Medicine and Healthcare products Regulatory Agency (MHRA) suspending all clinical trials of immunotherapy drugs and commissioning NIBSC, a government-funded institute, to investigate why both in vitro human cell tests and in vivo animal tests failed to predict the human immune system’s response to the drug.

“With hindsight testing this drug in man was a mistake, but at the time the standard required pre-clinical tests failed to predict the effects it would have on the six volunteers,” said Dr Poole, who said that the NIBSC’s group’s second paper on TGN1412 was due to be published shortly.

“While we are still investigating why the effect of this drug was so catastrophically different in the clinic than in pre-clinical testing, we have at least managed to develop new pre-clinical tests that should help us to avoid such outcomes in the future.”

Speaking at the British Pharmacological Society (BPS) conference, Dr Poole identifies new pre-clinical in vitro testing of immunotherapy drugs that should help prevent any repetition of the disastrous events that were witnessed at Northwick Park.

These measures include ensuring that such drugs are not tested solely on immune (white blood) cells in isolation. The NIBSC group has shown that having a mixed human cell culture of white blood cells and endothelial cells – the cells that line blood vessels – is a much better indicator of how this type of drug will react in vivo.

The NIBSC group has also developed a technique that dries the drug onto a plastic surface, rather than testing it on cells as a solution in water, which has proven to be a far more reliable indicator of how the drug will react in the human body.

“The aim of our research is to improve the preclinical testing of immunotherapy drugs on human cells in vitro, as well as to establish why the antibody was not toxic in pre-clinical testing,” said Dr Poole.

“We have made significant progress in designing new in vitro tests that hopefully will avoid the consequences that occurred at Northwick Park; indeed such tests could prevent harmful drugs of this type even reaching the animal-testing stage.”

Immunotherapy drugs have the potential to be incredibly important in the treatment of diseases that have so far eluded medical advances, including many forms of cancer, so it is vital that the scientific community has its faith in clinical trials and in immunotherapy fully restored.

Aeron Haworth | alfa
Further information:
http://www.bps.ac.uk
http://www.manchester.ac.uk

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>